Category: Uncategorized

Apr 30 2026

Uncategorized

FDA approves Caplyta for relapse prevention in schizophrenia

by Clinical Editor

No Comments

The FDA has approved Johnson & Johnson’s supplemental new drug application for Caplyta among patients with schizophrenia at risk for relapse, according to a press release from the company. Noting...

Apr 29 2026

Uncategorized

While we argue, schizophrenia advances – Nature

by Clinical Editor

No Comments

While we argue, schizophrenia advances  Nature

Apr 29 2026

Uncategorized

Caplyta Labeling Now Includes Long-Term Schizophrenia Maintenance Data

by Clinical Editor

No Comments

The FDA has updated the label for Caplyta to include phase 3 data showing a significant reduction in schizophrenia relapse risk.

Apr 28 2026

Uncategorized

Man with schizophrenia not criminally responsible for killing British tourist in Australia – The Times of India

by Clinical Editor

No Comments

Man with schizophrenia not criminally responsible for killing British tourist in Australia  The Times of India

Apr 28 2026

Uncategorized

FDA Approves sNDA of Caplyta for the Prevention of Relapse in Schizophrenia – Psychiatric Times

by Clinical Editor

No Comments

FDA Approves sNDA of Caplyta for the Prevention of Relapse in Schizophrenia  Psychiatric Times

Apr 26 2026

Uncategorized

UAMS Odyssey Clinic focuses on early intervention for schizophrenia, psychosis – KATV

by Clinical Editor

No Comments

UAMS Odyssey Clinic focuses on early intervention for schizophrenia, psychosis  KATV

Apr 26 2026

Uncategorized

“Reimagining what life with schizophrenia could look like” – Johnson & Johnson

by Clinical Editor

No Comments

“Reimagining what life with schizophrenia could look like”  Johnson & Johnson

Apr 25 2026

Uncategorized

Novel Antipsychotic Shows Promise in Acute Schizophrenia – MedPage Today

by Clinical Editor

No Comments

Novel Antipsychotic Shows Promise in Acute Schizophrenia  MedPage Today

Apr 25 2026

Uncategorized

Schizophrenia and accelerated ageing: systematic review and future research directions – Cambridge University Press & Assessment

by Clinical Editor

No Comments

Schizophrenia and accelerated ageing: systematic review and future research directions  Cambridge University Press & Assessment

Apr 24 2026

Uncategorized

Novel Antipsychotic Shows Promise in Acute Schizophrenia

by Clinical Editor

No Comments

Downsides with current options leave a large unmet need for new therapies, researcher says …